Brian L Sprague

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1412650/publications.pdf Version: 2024-02-01



RDIAN | SDDACHE

#	Article	IF	CITATIONS
1	National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology, 2017, 283, 49-58.	7.3	418
2	Body Mass Index and Breast Cancer Risk According to Postmenopausal Estrogen-Progestin Use and Hormone Receptor Status. Epidemiologic Reviews, 2014, 36, 114-136.	3.5	290
3	Prevalence of Mammographically Dense Breasts in the United States. Journal of the National Cancer Institute, 2014, 106, .	6.3	281
4	Identifying Women With Dense Breasts at High Risk for Interval Cancer. Annals of Internal Medicine, 2015, 162, 673-681.	3.9	215
5	Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Annals of Internal Medicine, 2016, 164, 215.	3.9	209
6	Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA - Journal of the American Medical Association, 2018, 319, 154.	7.4	209
7	Benefits, Harms, and Cost-Effectiveness of Supplemental Ultrasonography Screening for Women With Dense Breasts. Annals of Internal Medicine, 2015, 162, 157-166.	3.9	175
8	A Sustained Decline in Postmenopausal Hormone Use. Obstetrics and Gynecology, 2012, 120, 595-603.	2.4	169
9	Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer. JAMA Oncology, 2017, 3, 1228.	7.1	165
10	Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice. Annals of Internal Medicine, 2016, 165, 457.	3.9	148
11	Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium. Breast Cancer Research and Treatment, 2016, 156, 109-116.	2.5	147
12	Association of Digital Breast Tomosynthesis vs Digital Mammography With Cancer Detection and Recall Rates by Age and Breast Density. JAMA Oncology, 2019, 5, 635.	7.1	136
13	Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer, 2011, 117, 1542-1551.	4.1	124
14	Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality. Journal of the National Cancer Institute, 2014, 106, .	6.3	120
15	Screening ultrasound as an adjunct to mammography in women with mammographically dense breasts. American Journal of Obstetrics and Gynecology, 2015, 212, 9-17.	1.3	119
16	National Performance Benchmarks for Modern Diagnostic Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology, 2017, 283, 59-69.	7.3	102
17	Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Causes and Control, 2008, 19, 585-593.	1.8	100
18	Comparative Effectiveness of Combined Digital Mammography and Tomosynthesis Screening for Women with Dense Breasts. Radiology, 2015, 274, 772-780.	7.3	98

#	Article	IF	CITATIONS
19	Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma <i>In Situ</i> . Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 138-145.	2.5	94
20	Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. Journal of the National Cancer Institute, 2021, 113, 1484-1494.	6.3	92
21	Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes. Annals of Internal Medicine, 2016, 165, 700.	3.9	90
22	Circulating serum xenoestrogens and mammographic breast density. Breast Cancer Research, 2013, 15, R45.	5.0	86
23	Proportion of Invasive Breast Cancer Attributable to Risk Factors Modifiable after Menopause. American Journal of Epidemiology, 2008, 168, 404-411.	3.4	85
24	Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status. JAMA Oncology, 2015, 1, 1069.	7.1	85
25	Lifetime Recreational and Occupational Physical Activity and Risk of In situ and Invasive Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 236-243.	2.5	73
26	Changes in Mammography Use by Women's Characteristics During the First 5 Months of the COVID-19 Pandemic. Journal of the National Cancer Institute, 2021, 113, 1161-1167.	6.3	69
27	Screening Performance of Digital Breast Tomosynthesis vs Digital Mammography in Community Practice by Patient Age, Screening Round, and Breast Density. JAMA Network Open, 2020, 3, e2011792.	5.9	68
28	Performance Benchmarks for Screening Breast MR Imaging in Community Practice. Radiology, 2017, 285, 44-52.	7.3	66
29	Performance of Screening Ultrasonography as an Adjunct to Screening Mammography in Women Across the Spectrum of Breast Cancer Risk. JAMA Internal Medicine, 2019, 179, 658.	5.1	66
30	A Linkage Between Thyroid and Breast Cancer: A Common Etiology?. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 643-649.	2.5	62
31	Registry-based Study of Trends in Breast Cancer Screening Mammography before and after the 2009 U.S. Preventive Services Task Force Recommendations. Radiology, 2014, 270, 354-361.	7.3	59
32	The Contribution of Mammography Screening to Breast Cancer Incidence Trends in the United States: An Updated Age–Period–Cohort Model. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 905-912.	2.5	55
33	Genetic variation in TP53 and risk of breast cancer in a population-based case–control study. Carcinogenesis, 2007, 28, 1680-1686.	2.8	53
34	Comparing sensitivity and specificity of screening mammography in the <scp>U</scp> nited <scp>S</scp> tates and <scp>D</scp> enmark. International Journal of Cancer, 2015, 137, 2198-2207.	5.1	52
35	Long-Term Outcomes and Cost-Effectiveness of Breast Cancer Screening With Digital Breast Tomosynthesis in the United States. Journal of the National Cancer Institute, 2020, 112, 582-589. 	6.3	48
36	Surveillance Breast MRI and Mammography: Comparison in Women with a Personal History of Breast Cancer. Radiology, 2019, 292, 311-318.	7.3	46

#	Article	IF	CITATIONS
37	Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ. Breast Cancer Research and Treatment, 2010, 124, 487-495.	2.5	45
38	Trends of Postmenopausal Estrogen Plus Progestin Prevalence in the United States Between 1970 and 2010. Obstetrics and Gynecology, 2014, 124, 727-733.	2.4	43
39	The University of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update. Medical Decision Making, 2018, 38, 99S-111S.	2.4	43
40	Breast Cancer Population Attributable Risk Proportions Associated with Body Mass Index and Breast Density by Race/Ethnicity and Menopausal Status. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2048-2056.	2.5	41
41	Patient Satisfaction With Breast and Colorectal Cancer Survivorship Care Plans. Clinical Journal of Oncology Nursing, 2013, 17, 266-272.	0.6	40
42	Association between air pollution and mammographic breast density in the Breast Cancer Surveilance Consortium. Breast Cancer Research, 2017, 19, 36.	5.0	40
43	Airborne metals and polycyclic aromatic hydrocarbons in relation to mammographic breast density. Breast Cancer Research, 2019, 21, 24.	5.0	40
44	Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging. JAMA Internal Medicine, 2019, 179, 1230.	5.1	39
45	Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling. Medical Decision Making, 2018, 38, 9S-23S.	2.4	37
46	Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Internal Medicine, 2018, 178, 494.	5.1	36
47	Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 158-164.	2.5	36
48	Breast Cancer Screening Strategies for Women With <i>ATM, CHEK2</i> , and <i>PALB2</i> Pathogenic Variants. JAMA Oncology, 2022, 8, 587.	7.1	36
49	Geospatial and Temporal Analysis of Thyroid Cancer Incidence in a Rural Population. Thyroid, 2015, 25, 812-822.	4.5	35
50	Combining quantitative and qualitative breast density measures to assess breast cancer risk. Breast Cancer Research, 2017, 19, 97.	5.0	35
51	Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium. Journal of the National Cancer Institute, 2020, 112, 238-246.	6.3	35
52	Emerging Trends in Family History of Breast Cancer and Associated Risk. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1753-1760.	2.5	33
53	Breast, Cervical, and Colorectal Cancer Screening: Patterns Among Women With Medicaid and Commercial Insurance. American Journal of Preventive Medicine, 2019, 57, 394-402.	3.0	31
54	Circulating Sex Hormones and Mammographic Breast Density among Postmenopausal Women. Hormones and Cancer, 2011, 2, 62-72.	4.9	30

#	Article	IF	CITATIONS
55	One versus Two Breast Density Measures to Predict 5- and 10-Year Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 889-897.	2.5	30
56	Breast Cancer Characteristics Associated With Digital Versus Film-Screen Mammography for Screen-Detected and Interval Cancers. American Journal of Roentgenology, 2015, 205, 676-684.	2.2	30
57	Multilevel factors associated with long-term adherence to screening mammography in older women in the U.S Preventive Medicine, 2016, 89, 169-177.	3.4	30
58	Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis. Breast Cancer Research and Treatment, 2013, 138, 519-528.	2.5	29
59	Screening Mammography Outcomes: Risk of Breast Cancer and Mortality by Comorbidity Score and Age. Journal of the National Cancer Institute, 2020, 112, 599-606.	6.3	29
60	Assessment of Radiologist Performance in Breast Cancer Screening Using Digital Breast Tomosynthesis vs Digital Mammography. JAMA Network Open, 2020, 3, e201759.	5.9	28
61	Comparative Access to and Use of Digital Breast Tomosynthesis Screening by Women's Race/Ethnicity and Socioeconomic Status. JAMA Network Open, 2021, 4, e2037546.	5.9	28
62	Multilevel Factors Associated With Time to Biopsy After Abnormal Screening Mammography Results by Race and Ethnicity. JAMA Oncology, 2022, 8, 1115.	7.1	28
63	Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study. Breast Cancer Research and Treatment, 2013, 141, 145-154.	2.5	27
64	Increased Risk of Developing Breast Cancer after a False-Positive Screening Mammogram. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1882-1889.	2.5	27
65	The Effect of Change in Body Mass Index on Volumetric Measures of Mammographic Density. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1724-1730.	2.5	26
66	The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer. Cancer Causes and Control, 2011, 22, 125-134.	1.8	25
67	Association of Screening With Digital Breast Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer. JAMA - Journal of the American Medical Association, 2022, 327, 2220.	7.4	25
68	Beyond BI-RADS Density: A Call for Quantification in the Breast Imaging Clinic. Radiology, 2018, 286, 401-404.	7.3	24
69	Digital Breast Tomosynthesis: Radiologist Learning Curve. Radiology, 2019, 291, 34-42.	7.3	24
70	The Role of Social Determinants of Health in Self-Reported Access to Health Care Among Women Undergoing Screening Mammography. Journal of Women's Health, 2020, 29, 1437-1446.	3.3	23
71	Prevalence of Breast Carcinoma In Situ in the United States. JAMA - Journal of the American Medical Association, 2009, 302, 846.	7.4	22
72	Contribution of Breast Cancer to Overall Mortality for US Women. Medical Decision Making, 2018, 38, 24S-31S.	2.4	22

#	Article	IF	CITATIONS
73	Survey Results Regarding Uptake and Impact of Synthetic Digital Mammography With Tomosynthesis in the Screening Setting. Journal of the American College of Radiology, 2020, 17, 31-37.	1.8	22
74	The vitamin D pathway and mammographic breast density among postmenopausal women. Breast Cancer Research and Treatment, 2012, 131, 255-265.	2.5	21
75	Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium. Journal of the National Cancer Institute, 2021, 113, 909-916.	6.3	21
76	Collagen Organization in Relation to Ductal Carcinoma <i>In Situ</i> Pathology and Outcomes. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 80-88.	2.5	21
77	Association of Breast Density With Breast Cancer Risk Among Women Aged 65 Years or Older by Age Group and Body Mass Index. JAMA Network Open, 2021, 4, e2122810.	5.9	21
78	Breast Biopsy Recommendations and Breast Cancers Diagnosed during the COVID-19 Pandemic. Radiology, 2022, 303, 287-294.	7.3	21
79	Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography. JAMA Network Open, 2022, 5, e222440.	5.9	21
80	Breast Cancer With a Poor Prognosis Diagnosed After Screening Mammography With Negative Results. JAMA Oncology, 2018, 4, 998.	7.1	20
81	Multicenter Evaluation of Breast Cancer Screening with Digital Breast Tomosynthesis in Combination with Synthetic versus Digital Mammography. Radiology, 2020, 297, 545-553.	7.3	20
82	Identifying key barriers to effective breast cancer control in rural settings. Preventive Medicine, 2021, 152, 106741.	3.4	20
83	Comparison of false positive rates for screening breast magnetic resonance imaging (MRI) in high risk women performed on stacked versus alternating schedules. SpringerPlus, 2015, 4, 77.	1.2	19
84	Emerging trends in surgical and adjuvant radiation therapies among women diagnosed with ductal carcinoma in situ. Cancer, 2016, 122, 2810-2818.	4.1	19
85	Prioritizing breast imaging services during the COVID pandemic: A survey of breast imaging facilities within the Breast Cancer Surveillance Consortium. Preventive Medicine, 2021, 151, 106540.	3.4	19
86	Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population. Journal of the National Cancer Institute, 2022, 114, 676-685.	6.3	18
87	Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention. PLoS ONE, 2017, 12, e0168601.	2.5	16
88	Breast MRI BI-RADS Assessments and Abnormal Interpretation Rates by Clinical Indication in US Community Practices. Academic Radiology, 2014, 21, 1370-1376.	2.5	15
89	Detection Rates for Benign and Malignant Diagnoses on Breast Cancer Screening With Digital Breast Tomosynthesis in a Statewide Mammography Registry Study. American Journal of Roentgenology, 2019, 212, 706-711.	2.2	15
90	Comparison of cumulative false-positive risk of screening mammography in the United States and Denmark. Cancer Epidemiology, 2015, 39, 656-663.	1.9	14

#	Article	IF	CITATIONS
91	Characterizing the intersection of Co-occurring risk factors for illicit drug abuse and dependence in a U.S. nationally representative sample. Preventive Medicine, 2016, 92, 118-125.	3.4	13
92	Communication Practices of Mammography Facilities and Timely Follow-up of a Screening Mammogram with a BI-RADS 0 Assessment. Academic Radiology, 2018, 25, 1118-1127.	2.5	13
93	Cost-Effectiveness of Screening Mammography Beyond Age 75 Years. Annals of Internal Medicine, 2022, 175, 11-19.	3.9	13
94	The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ. Npj Breast Cancer, 2022, 8, 6.	5.2	13
95	Primary Care Provider Evaluation of Cancer Survivorship Care Plans Developed for Patients in their Practice. Journal of General Practice (Los Angeles, Calif), 2014, 02, 163.	0.1	12
96	The impact of mammographic screening on the surgical management of breast cancer. Journal of Surgical Oncology, 2016, 113, 496-500.	1.7	12
97	Cancer Models and Real-world Data: Better Together: Table 1 Journal of the National Cancer Institute, 2016, 108, djv316.	6.3	12
98	Time-varying risks of second events following a DCIS diagnosis in the population-based Vermont DCIS cohort. Breast Cancer Research and Treatment, 2019, 174, 227-235.	2.5	12
99	Ductal Carcinoma In Situ: A Brief Review of Treatment Variation and Impacts on Patients and Society. Critical Reviews in Eukaryotic Gene Expression, 2014, 24, 281-286.	0.9	11
100	Access to Care in Vermont: Factors Linked With Time to Chemotherapy for Women With Breast Cancer—A Retrospective Cohort Study. Journal of Oncology Practice, 2016, 12, e848-e857.	2.5	11
101	New mammography screening performance metrics based on the entire screening episode. Cancer, 2020, 126, 3289-3296.	4.1	11
102	Health-related behaviors and mortality outcomes in women diagnosed with ductal carcinoma in situ. Journal of Cancer Survivorship, 2017, 11, 320-328.	2.9	10
103	Change in Breast Cancer Screening Intervals Since the 2009 USPSTF Guideline. Journal of Women's Health, 2017, 26, 820-827.	3.3	10
104	Multilevel Predictors of Continued Adherence to Breast Cancer Screening Among Women Ages 50–74 Years in a Screening Population. Journal of Women's Health, 2019, 28, 1051-1059.	3.3	10
105	Comparing Mammographic Density Assessed by Digital Breast Tomosynthesis or Digital Mammography: The Breast Cancer Surveillance Consortium. Radiology, 2021, , 204579.	7.3	10
106	Facility Variability in Examination Indication Among Women With Prior Breast Cancer: Implications and the Need for Standardization. Journal of the American College of Radiology, 2020, 17, 755-764.	1.8	9
107	Assessment of a Risk-Based Approach for Triaging Mammography Examinations During Periods of Reduced Capacity. JAMA Network Open, 2021, 4, e211974.	5.9	9
108	Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women. Journal of the National Cancer Institute, 2021, 113, 1017-1026.	6.3	9

#	Article	IF	CITATIONS
109	Diagnostic imaging and biopsy pathways following abnormal screen-film and digital screening mammography. Breast Cancer Research and Treatment, 2013, 138, 879-887.	2.5	7
110	Advanced Breast Imaging Availability by Screening Facility Characteristics. Academic Radiology, 2015, 22, 846-852.	2.5	7
111	Partnership Status and Socioeconomic Factors in Relation to Health Behavior Changes after a Diagnosis of Ductal Carcinoma <i>In Situ</i> . Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 76-82.	2.5	7
112	The Effect of Digital Breast Tomosynthesis Adoption on Facility-Level Breast Cancer Screening Volume. American Journal of Roentgenology, 2018, 211, 957-963.	2.2	7
113	Patterns of Breast Imaging Use Among Women with a Personal History of Breast Cancer. Journal of General Internal Medicine, 2019, 34, 2098-2106.	2.6	7
114	Mammographic Breast Density and Serum Phytoestrogen Levels. Nutrition and Cancer, 2012, 64, 783-789.	2.0	6
115	Health behavior change following a diagnosis of ductal carcinoma in situ: An opportunity to improve health outcomes. Preventive Medicine, 2015, 80, 53-59.	3.4	6
116	Breast cancer screening initiation after turning 40Âyears of age within the PROSPR consortium. Breast Cancer Research and Treatment, 2016, 160, 323-331.	2.5	6
117	Concordance of BI-RADS Assessments and Management Recommendations for Breast MRI in Community Practice. American Journal of Roentgenology, 2016, 206, 211-216.	2.2	5
118	The association between post-diagnosis health behaviors and long-term quality of life in survivors of ductal carcinoma in situ: a population-based longitudinal cohort study. Quality of Life Research, 2018, 27, 1237-1247.	3.1	5
119	Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening. Breast Cancer Research and Treatment, 2018, 168, 229-239.	2.5	4
120	The Shared Core Resource as a Partner in Innovative Scientific Research: Illustration from an Academic Microscopy Imaging Center. Journal of Biomolecular Techniques, 2022, 33, 3fc1f5fe.2507f36c.	1.5	4
121	Changes in Breast Cancer Risk Distribution Among Vermont Women Using Screening Mammography. Journal of the National Cancer Institute, 2014, 106, dju157-dju157.	6.3	3
122	Investigation of Mammographic Breast Density as a Risk Factor for Ovarian Cancer. Journal of the National Cancer Institute, 2014, 106, djt341-djt341.	6.3	3
123	Function-related Indicators and Outcomes of Screening Mammography in Older Women: Evidence from the Breast Cancer Surveillance Consortium Cohort. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1582-1590.	2.5	3
124	State-level rurality and cigarette smoking-associated cancer incidence and mortality: Do individual-level trends translate to population-level outcomes?. Preventive Medicine, 2021, 152, 106759.	3.4	3
125	Breast Density Knowledge in a Screening Mammography Population Exposed to Density Notification. Journal of the American College of Radiology, 2022, 19, 615-624.	1.8	3
126	Diagnostic Mammography Performance across Racial and Ethnic Groups in a National Network of Community-Based Breast Imaging Facilities. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1324-1333.	2.5	3

#	Article	IF	CITATIONS
127	Serum Factors and Clinical Characteristics Associated with Serum E-Screen Activity. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 962-971.	2.5	2
128	Mammography adherence in relation to function-related indicators in older women. Preventive Medicine, 2022, 154, 106869.	3.4	2
129	Gradual adoption of needle biopsy for breast lesions in a rural state. Cancer Medicine, 2021, 10, 8320-8327.	2.8	1
130	The Business of Research: Budgets, Personnel, Planning, and Pitfalls—a Report from the American Society of Preventive Oncology's Junior Members Interest Group. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1802-1804.	2.5	0
131	Response to Pisano, Gastonis, Sparano, et al. Journal of the National Cancer Institute, 2021, 113, 940-941.	6.3	Ο
132	Abstract 2531: Function-related indicator and outcomes of screening mammography in older women from the BCSC-Medicare Cohort. , 2021, , .		0
133	67â€Breast biopsy patterns and findings among older women undergoing screening mammography: what is the impact of age and comorbidity?. , 2019, , .		0